Midodrine for the weaning of vasopressor infusions
Authors:
- 4 March 2016
- journal article
- Published by Hindawi Limited in Journal of Clinical Pharmacy and Therapeutics
- Vol. 41 (3) , 260-265
Abstract
Midodrine, an orally available α1-agonist indicated for the treatment of orthostatic hypotension, has been used at our institution as an adjunctive treatment to provide haemodynamic support to facilitate intravenous (IV) vasopressor weaning. Limited published data exist for this off-label use; thus, the objective of this study was to evaluate outcomes in patients who received midodrine for IV vasopressor weaning compared to control patients. This retrospective comparison included adult ICU patients admitted to our institution from January 2007 to March 2012. The primary outcome was the time to IV vasopressor discontinuation after midodrine initiation. Secondary outcomes included a comparison between midodrine and control patients of the time from IV vasopressor discontinuation to ICU discharge, hospital and ICU length of stay (LOS), and the number of ICU readmissions. The analysis included 188 patients (94 midodrine and 94 control). Patients discontinued IV vasopressors a median of 1·2 days (IQR 0·5-2·8) after midodrine initiation. ICU discharge occurred sooner after IV vasopressor discontinuation (0·8 vs. 1·5 days, P = 0·01), and 96% of patients remained off IV vasopressors after midodrine treatment. Hospital LOS was longer in midodrine patients (P < 0·01), but there were no differences in ICU LOS or readmissions. Adverse event rates after midodrine use were consistent with those observed in other studies. Midodrine may serve as a useful adjunct to wean IV vasopressors in difficult-to-wean patients. Further studies are needed to assess the efficacy and safety of midodrine for this indication.Keywords
This publication has 16 references indexed in Scilit:
- Use of inotropes and vasopressor agents in critically ill patientsBritish Journal of Pharmacology, 2012
- Midodrine in patients with cirrhosis and refractory or recurrent ascites: A randomized pilot studyJournal of Hepatology, 2012
- Effectiveness of Midodrine treatment in patients with recurrent vasovagal syncope not responding to non-pharmacological treatment (STAND-trial)EP Europace, 2011
- Midodrine Hydrochloride Is Effective in the Treatment of Children With Postural Orthostatic Tachycardia SyndromeCirculation Journal, 2011
- Inotropes and VasopressorsCirculation, 2008
- Octreotide/Midodrine Therapy Significantly Improves Renal Function and 30-Day Survival in Patients with Type 1 Hepatorenal SyndromeDigestive Diseases and Sciences, 2007
- Midodrine, an alternative to intravenous vasopressor therapy after spinal surgeryEuropean Journal of Anaesthesiology, 2002
- A double-blind, dose-response study of midodrine in neurogenic orthostatic hypotensionNeurology, 1998
- Efficacy of Midodrine vs Placebo in Neurogenic Orthostatic HypotensionJAMA, 1997
- Pharmacodynamics of midodrine, an antihypotensive agentClinical Pharmacology & Therapeutics, 1986